knowledge -WSS

knowledge

author：entertainment 2025-09-27 11:58:18 - browse：4

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Microbiome research is starting to find links to chronic diseases

knowledge

hotspot

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Chimpanzees, like humans and whales, get menopause: Study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Physician subsidies by hospitals soar in wake of No Surprises Act

Wikipedia

knowledge

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

The FDA weighs the risks of candy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Microbiome research is starting to find links to chronic diseases

Anesthesiologist group: stop taking Ozempic before surgery

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Apple is now the first public company to be valued at $3 trillion

WHO may add ‘noma' to its list of neglected tropical diseases

In Memoriam: Notable people who died in 2023

Eli Lilly to pay $200M for Beam’s stake in gene

hotspot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Readout Newsletter: New research from Sanofi, Regeneron, etc.

CommonSpirit Health keeps growing, even as it loses money

CommonSpirit Health keeps growing, even as it loses money

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Senate panel to vote on hospitals, PBMs, prisoner care

explore

knowledge

hotspot

hotspot